文献速递治疗药物监测与药物基因组学

药物基因组学研究揭示UGT1A3在孟鲁司特药代动力学中的重要作用

Comprehensive Pharmacogenomic Study Reveals an Important Role of UGT1A3 in Montelukast Pharmacokinetics.
PubMed 文献 · Clin Pharmacol Ther · 2017-11-06

该研究在191名健康志愿者中测定孟鲁司特药代动力学并测序379个药代动力学基因,发现与UGT1A3*2强连锁的内含子SNV与孟鲁司特AUC0-∞降低相关(每个次要等位基因拷贝降低18%,P=1.83×10-10)。UGT1A3*2还与孟鲁司特酰基葡萄糖醛酸代谢物M1的AUC0-∞升高及羟基代谢物M5R、M5S、M6的AUC0-∞降低相关(P<10-9)。SLCO1B1和ABCC9的SNV分别与M1和M5R的AUC0-∞相关,提示UGT1A3在孟鲁司特处置中起重要作用,尤其在UGT1A3*2携带者中。

要点

  • UGT1A3*2携带者孟鲁司特AUC0-∞降低,每个次要等位基因拷贝降低18%。
  • UGT1A3*2与M1的AUC0-∞升高及M5R、M5S、M6的AUC0-∞降低相关。
  • SLCO1B1和ABCC9的SNV分别与M1和M5R的AUC0-∞相关。

核心结论

  • UGT1A3在孟鲁司特药代动力学中起重要作用,尤其在UGT1A3*2携带者中。

研究设计与样本

  • 在191名健康志愿者中测定孟鲁司特药代动力学并对379个药代动力学基因进行测序。

主要发现

  • 与UGT1A3*2强连锁的内含子SNV与孟鲁司特AUC0-∞降低相关,每个次要等位基因拷贝降低18%(P=1.83×10-10)。
  • UGT1A3*2与孟鲁司特酰基葡萄糖醛酸M1的AUC0-∞升高及羟基代谢物M5R、M5S、M6的AUC0-∞降低相关(P<10-9)。
  • SLCO1B1和ABCC9的SNV分别与M1和M5R的AUC0-∞相关。
  • 候选基因分析提示CYP2C8和ABCC9的SNV也影响孟鲁司特AUC0-∞。
  • UGT1A3和ABCC9变异与人肝样本中相应基因表达增加相关,且孟鲁司特及其羟基代谢物在体外被UGT1A3葡萄糖醛酸化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To identify the genetic basis of interindividual variability in montelukast exposure, we determined its pharmacokinetics and sequenced 379 pharmacokinetic genes in 191 healthy volunteers. An intronic single nucleotide variation (SNV), strongly linked with UGT1A3*2, associated with reduced area under the plasma concentration-time curve (AUC0-∞ ) of montelukast (by 18% per copy of the minor allele; P = 1.83 × 10-10 ). UGT1A3*2 was associated with increased AUC0-∞ of montelukast acyl-glucuronide M1 and decreased AUC0-∞ of hydroxymetabolites M5R, M5S, and M6 (P < 10-9 ). Furthermore, SNVs in SLCO1B1 and ABCC9 were associated with the AUC0-∞ of M1 and M5R, respectively. In addition, a candidate gene analysis suggested that CYP2C8 and ABCC9 SNVs also affect the AUC0-∞ of montelukast. The found UGT1A3 and ABCC9 variants associated with increased expression of the respective genes in human liver samples. Montelukast and its hydroxymetabolites were glucuronidated by UGT1A3 in vitro. These results indicate that UGT1A3 plays an important role in montelukast pharmacokinetics, especially in UGT1A3*2 carriers.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Hirvensalo P, Tornio A, Neuvonen M, et al. Comprehensive Pharmacogenomic Study Reveals an Important Role of UGT1A3 in Montelukast Pharmacokinetics. Clin Pharmacol Ther. 2017. PMID: 28940478. doi:10.1002/cpt.891

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。